Drug Patents owned by Abbvie

1. Drug name - ANDROGEL

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8729057 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8754070 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8466137 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8759329 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8486925 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8466136 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8466138 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

US8741881 ABBVIE Testosterone gel and method of use Oct, 2026

(4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

More Information on Dosage
Strength Dosage Availability
1.62% (20.25MG/1.25GM ACTUATION) GEL, METERED;TRANSDERMAL Prescription
1.62% (20.25MG/1.25GM PACKET) GEL;TRANSDERMAL Discontinued
1.62% (40.5MG/2.5GM PACKET) GEL;TRANSDERMAL Discontinued

2. Drug name - TRICOR

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7320802 ABBVIE Methods of treatment using nanoparticulate fenofibrate compositions Feb, 2023

(4 months from now)

US7276249 ABBVIE Nanoparticulate fibrate formulations Feb, 2023

(4 months from now)

Drugs and Companies using FENOFIBRATE ingredient

Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hypertriglyceridemia (types iv, v)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
48MG TABLET;ORAL Prescription
145MG TABLET;ORAL Prescription

3. Drug name - TRILIPIX

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7259186 ABBVIE Salts of fenofibric acid and pharmaceutical formulations thereof
Jan, 2025

(2 years from now)

CN101480384A ABBVIE Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Thereof
Apr, 2012

(10 years ago)

CN1726024A ABBVIE Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Preparation
Dec, 2023

(1 year, 2 months from now)

CN100473378C ABBVIE Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Preparation
Dec, 2023

(1 year, 2 months from now)

EP1572190A1 ABBVIE Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Thereof
Dec, 2023

(1 year, 2 months from now)

EP1572190B1 ABBVIE Formulation Comprising Fenofibric Acid, A Physiologically Acceptable Salt Or Derivative Thereof
Dec, 2023

(1 year, 2 months from now)

Drugs and Companies using CHOLINE FENOFIBRATE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 45MG FENOFIBRIC ACID CAPSULE, DELAYED RELEASE;ORAL Prescription
EQ 135MG FENOFIBRIC ACID CAPSULE, DELAYED RELEASE;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.